Next-Gen Biotech Platforms Bu dilim, daha geniş Healthcare & Biotech temasının bir parçasıdır.
Next-Gen Biotech Platforms hisseleri genelde Healthcare & Biotech temasının geri kalanından farklı sürücülere tepki verir. Bu segmenti ayırmak, kazanç mantığını ve haber akışını değer zincirinin tek bir parçasıyla hizalar.
Üyelik Next Big Trend sınıflandırmasına dayanır: Healthcare & Biotech → Next-Gen Biotech Platforms. Tarayıcı filtrelerini yeniden kurmadan güncellemeleri izlemek için listeyi kaydedin.
| Şirket | |||||||
|---|---|---|---|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Incorporated | $130.1B | -3.28% | -4.40% | +11.53% | +25.50% | 64 |
| TAK | Takeda Pharmaceutical Company Limited | $58.7B | +0.99% | +0.27% | +17.83% | +26.25% | 75 |
| TEVA | Teva Pharmaceutical Industries Limited | $45.7B | -1.06% | +6.58% | +25.54% | +96.29% | 87 |
| ALNY | Alnylam Pharmaceuticals, Inc. | $33.0B | -9.05% | -13.72% | -43.57% | -50.35% | 42 |
| RPRX | Royalty Pharma plc | $32.6B | -2.74% | -6.32% | +48.32% | +59.50% | 59 |
| ZTS | Zoetis Inc. | $30.2B | +2.46% | -2.73% | -42.24% | -49.83% | 68 |
| WST | West Pharmaceutical Services, Inc. | $25.5B | -1.15% | +8.51% | +33.51% | +37.14% | 89 |
| UTHR | United Therapeutics Corporation | $21.4B | +0.57% | +9.44% | +11.85% | +20.23% | 90 |
| JAZZ | Jazz Pharmaceuticals plc | $15.0B | -0.14% | -3.70% | +35.99% | +68.04% | 65 |
| ASND | Ascendis Pharma A/S | $14.7B | +0.25% | -15.43% | +7.11% | +8.34% | 38 |
| NBIX | Neurocrine Biosciences, Inc. | $14.6B | +1.15% | -7.52% | +1.16% | +2.90% | 55 |
| SMMT | Summit Therapeutics Inc. | $14.3B | +6.15% | +3.88% | +2.63% | -18.96% | 84 |
| BBIO | BridgeBio Pharma, Inc. | $13.0B | +1.06% | -11.05% | -13.06% | +21.77% | 47 |
| HALO | Halozyme Therapeutics, Inc. | $12.7B | +0.35% | +2.29% | +64.62% | +65.43% | 81 |
| CORT | Corcept Therapeutics Incorporated | $12.6B | +3.79% | +4.93% | +243.68% | +168.52% | 85 |
| BMRN | BioMarin Pharmaceutical Inc. | $11.9B | -8.00% | -14.59% | -7.12% | -0.74% | 40 |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.5B | -3.22% | -8.69% | -16.25% | +10.27% | 51 |
| AXSM | Axsome Therapeutics, Inc. | $10.3B | -6.19% | -16.77% | -5.29% | +44.21% | 36 |
| KRYS | Krystal Biotech, Inc. | $9.6B | -2.40% | -7.60% | +31.65% | +79.75% | 54 |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $9.4B | -6.07% | -27.76% | -7.40% | +63.95% | 18 |
| KYMR | Kymera Therapeutics, Inc. | $9.2B | -3.08% | -6.97% | +39.25% | +88.27% | 56 |
| PTGX | Protagonist Therapeutics, Inc. | $9.1B | +0.02% | -3.44% | +61.35% | +119.71% | 67 |
| TGTX | TG Therapeutics, Inc. | $8.1B | -5.07% | -5.01% | +77.62% | +44.04% | 62 |
| IONS | Ionis Pharmaceuticals, Inc. | $7.4B | -1.10% | -22.13% | -44.18% | -36.02% | 26 |
| SYRE | Spyre Therapeutics, Inc. | $7.0B | -9.19% | -10.95% | +146.79% | +385.00% | 48 |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.7B | -2.43% | +15.25% | +55.95% | +86.26% | 93 |
| IOVA | Iovance Biotherapeutics, Inc. | $6.7B | -12.85% | +48.45% | +373.08% | +484.39% | 98 |
| RYTM | Rhythm Pharmaceuticals, Inc. | $6.2B | -7.10% | -13.11% | -17.37% | -9.62% | 43 |
| LGND | Ligand Pharmaceuticals Incorporated | $6.0B | -6.12% | +1.53% | +55.11% | +60.59% | 79 |
| TVTX | Travere Therapeutics, Inc. | $6.0B | -9.24% | -19.12% | +39.86% | +104.52% | 31 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $5.8B | +4.49% | +1.13% | +88.99% | +103.60% | 78 |
| COGT | Cogent Biosciences, Inc. | $5.6B | -5.87% | -14.57% | -15.15% | -13.45% | 40 |
| ORKA | Oruka Therapeutics, Inc. | $5.6B | -4.55% | -15.70% | +162.29% | +291.05% | 38 |
| XENE | Xenon Pharmaceuticals Inc. | $5.5B | -2.10% | -38.86% | -18.76% | -7.94% | 7 |
| MIRM | Mirum Pharmaceuticals, Inc. | $5.4B | -5.66% | -18.98% | +2.09% | +11.18% | 32 |
| PTCT | PTC Therapeutics, Inc. | $5.3B | -2.39% | -8.11% | -16.76% | -2.42% | 53 |
| DFTX | Definium Therapeutics, Inc. | $5.2B | -7.80% | -8.21% | +162.06% | +187.15% | 52 |
| MANE | Veradermics, Incorporated | $4.9B | -8.48% | +6.86% | +193.91% | — | 87 |
| DNTH | Dianthus Therapeutics, Inc. | $4.8B | -3.60% | -22.22% | +105.97% | +146.31% | 26 |
| ADPT | Adaptive Biotechnologies Corporation | $4.5B | -9.07% | +7.97% | +61.82% | +81.62% | 88 |
| ACAD | ACADIA Pharmaceuticals Inc. | $4.4B | -2.48% | -28.75% | -26.43% | -8.99% | 16 |
| EWTX | Edgewise Therapeutics, Inc. | $4.3B | -2.54% | -9.70% | +59.46% | +157.79% | 49 |
| INDV | Indivior Pharmaceuticals, Inc. | $4.2B | +0.78% | +5.27% | +0.70% | +58.95% | 86 |
| RLAY | Relay Therapeutics, Inc. | $4.1B | -0.55% | -6.07% | +112.17% | +221.11% | 59 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.9B | -5.74% | -19.04% | +127.07% | +116.15% | 32 |
| TLX | Telix Pharmaceuticals Limited | $3.8B | +1.37% | -7.18% | +48.46% | +9.23% | 56 |
| LEGN | Legend Biotech Corporation | $3.8B | -3.87% | -6.69% | -12.05% | -39.19% | 58 |
| IDYA | IDEAYA Biosciences, Inc. | $3.7B | -5.62% | -6.64% | +4.89% | +31.90% | 58 |
| TNGX | Tango Therapeutics, Inc. | $3.7B | -12.51% | -3.83% | +146.39% | +187.99% | 65 |
| PLSE | Pulse Biosciences, Inc | $3.6B | -1.66% | +0.61% | +257.54% | +152.39% | 76 |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.4B | -6.36% | -15.60% | -10.10% | +8.71% | 38 |
| VKTX | Viking Therapeutics, Inc. | $3.4B | -12.45% | -15.26% | -18.87% | -11.59% | 39 |
| ELVN | Enliven Therapeutics, Inc. | $3.4B | -9.77% | -30.34% | +168.57% | +103.74% | 15 |
| DNLI | Denali Therapeutics Inc. | $3.4B | -7.31% | -13.22% | +16.05% | +25.89% | 43 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | -8.55% | -0.90% | -16.77% | +22.32% | 72 |
| RCUS | Arcus Biosciences, Inc. | $3.1B | -5.07% | -15.62% | +2.90% | +69.34% | 38 |
| DYN | Dyne Therapeutics, Inc. | $3.1B | -0.87% | -21.37% | -18.35% | +26.25% | 27 |
| NAMS | NewAmsterdam Pharma Company N.V. | $2.8B | -9.00% | -13.66% | -36.92% | -31.87% | 42 |
| MBX | MBX Biosciences, Inc. | $2.7B | -6.96% | -11.63% | +72.92% | +226.78% | 47 |
| GRDN | Guardian Pharmacy Services, Inc. | $2.6B | -0.25% | -0.22% | +35.19% | +69.92% | 74 |
| BEAM | Beam Therapeutics Inc. | $2.5B | +1.31% | -7.68% | -10.64% | -4.33% | 54 |
| VRDN | Viridian Therapeutics, Inc. | $2.5B | -11.22% | -21.10% | -41.26% | -12.24% | 28 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.5B | +0.02% | +1.46% | -13.38% | -10.89% | 79 |
| RXRX | Recursion Pharmaceuticals, Inc. | $2.5B | +3.39% | +24.13% | +4.40% | -22.78% | 95 |
| CLDX | Celldex Therapeutics, Inc. | $2.4B | -6.11% | -22.21% | +12.04% | +15.35% | 26 |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | -4.13% | -13.01% | +19.82% | +128.44% | 44 |
| GPCR | Structure Therapeutics Inc. | $2.3B | -14.68% | -33.93% | -61.64% | -54.06% | 11 |
| VERA | Vera Therapeutics, Inc. | $2.3B | -6.32% | -14.26% | -40.26% | -2.23% | 41 |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.3B | +0.20% | -6.49% | +5.13% | +47.95% | 58 |
| SLS | SELLAS Life Sciences Group, Inc. | $2.3B | -8.12% | -18.98% | +200.00% | +498.41% | 32 |
| AUPH | Aurinia Pharmaceuticals Inc | $2.2B | -1.14% | -0.37% | +0.38% | +41.43% | 73 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.2B | +0.84% | -7.34% | +7.69% | +19.66% | 55 |
| URGN | UroGen Pharma Ltd. | $2.1B | +0.17% | -7.11% | +73.78% | +138.71% | 56 |
| ZBIO | Zenas BioPharma, Inc. | $2.1B | +4.49% | -14.74% | +61.20% | +154.15% | 40 |
| MLYS | Mineralys Therapeutics, Inc. | $2.1B | -12.10% | -29.02% | -39.13% | -41.88% | 16 |
| AGIO | Agios Pharmaceuticals, Inc. | $2.0B | -4.39% | -5.25% | +16.79% | +58.31% | 61 |
| GENB | Generate Biomedicines, Inc. | $2.0B | -9.65% | -14.65% | +7.27% | — | 40 |
| LKFT | Lakefront Biotherapeutics | $1.9B | +1.18% | +8.58% | -8.26% | -15.61% | 89 |
| TRVI | Trevi Therapeutics, Inc. | $1.9B | -8.24% | -21.88% | +4.95% | +32.06% | 27 |
| SRPT | Sarepta Therapeutics, Inc. | $1.8B | -3.95% | -16.43% | -18.68% | -24.76% | 37 |
| PVLA | Palvella Therapeutics, Inc. | $1.8B | -5.32% | -14.24% | +24.76% | +92.19% | 41 |
| VIR | Vir Biotechnology, Inc. | $1.8B | +3.04% | +3.04% | +91.04% | +106.08% | 82 |
| NTLA | Intellia Therapeutics, Inc. | $1.7B | -2.90% | -8.08% | +30.26% | -42.99% | 53 |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | -0.99% | +2.42% | -8.88% | -21.87% | 81 |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | +6.58% | -7.52% | +224.54% | +164.74% | 55 |
| TYRA | Tyra Biosciences, Inc. | $1.7B | -6.77% | -23.72% | -22.44% | +51.82% | 25 |
| STOK | Stoke Therapeutics, Inc. | $1.6B | -6.58% | -19.17% | -23.47% | -9.40% | 31 |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.5B | -9.41% | -14.59% | -18.94% | +3.84% | 40 |
| RAPP | Rapport Therapeutics, Inc. | $1.5B | -8.15% | -33.04% | +1.71% | +11.25% | 12 |
| NKTR | Nektar Therapeutics | $1.5B | -33.50% | -46.63% | -4.78% | -32.82% | 3 |
| AVBP | ArriVent BioPharma, Inc. | $1.5B | -44.22% | -44.22% | -16.05% | -15.34% | 4 |
| MAZE | Maze Therapeutics, Inc. | $1.5B | -3.42% | -0.46% | -36.64% | -4.61% | 73 |
| INBX | Inhibrx Biosciences, Inc. | $1.5B | -6.71% | -18.35% | +18.18% | +32.20% | 34 |
| AAPG | Ascentage Pharma Group International - American Depository Shares | $1.5B | -8.40% | -14.33% | -43.06% | -62.52% | 41 |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.4B | -0.93% | +0.07% | -35.26% | -50.68% | 75 |
| XERS | Xeris Biopharma Holdings, Inc. | $1.4B | +5.75% | +19.22% | +28.79% | +24.35% | 94 |
| DRTS | Alpha Tau Medical Ltd. | $1.4B | -4.43% | -3.98% | +187.88% | +237.68% | 65 |
| OMER | Omeros Corporation | $1.4B | -1.52% | -1.94% | +9.14% | +306.72% | 70 |
| BCAX | Bicara Therapeutics Inc. | $1.3B | -11.77% | -30.75% | -2.44% | -8.93% | 14 |
| VOR | Vor Biopharma Inc. | $1.3B | -1.57% | -25.18% | +43.58% | +0.55% | 23 |
| ORIC | Oric Pharmaceuticals, Inc. | $1.3B | -10.84% | -4.83% | +46.82% | -16.66% | 62 |
| DMRA | Damora Therapeutics, Inc. | $1.3B | -4.89% | -30.61% | -12.04% | +10.56% | 14 |
| PIII | P3 Health Partners Inc. | $1.3B | -16.78% | -37.31% | -42.42% | -77.45% | 8 |
| REPL | Replimune Group, Inc. | $1.2B | -0.30% | -10.63% | -1.08% | +3.35% | 48 |
| LBRX | LB Pharmaceuticals Inc | $1.2B | -11.00% | -30.84% | +53.46% | +125.63% | 14 |
| CSTL | Castle Biosciences, Inc. | $1.1B | -7.12% | +0.73% | -15.17% | +41.57% | 77 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $1.1B | -1.05% | +11.38% | -4.63% | -3.91% | 91 |
| JANX | Janux Therapeutics, Inc. | $1.1B | +3.70% | -10.58% | +29.86% | +68.74% | 48 |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.0B | -14.75% | -28.73% | -35.14% | +32.77% | 16 |
| PCRX | Pacira BioSciences, Inc. | $986M | +0.60% | -2.59% | -2.63% | +5.57% | 69 |
| CRVS | Corvus Pharmaceuticals, Inc. | $977M | -9.64% | -25.27% | -49.17% | -43.92% | 23 |
| MLTX | MoonLake Immunotherapeutics | $971M | -7.95% | -27.91% | -18.29% | +24.36% | 18 |
| ABUS | Arbutus Biopharma Corporation | $961M | -10.25% | -17.18% | -10.81% | -1.15% | 35 |
| CGEM | Cullinan Therapeutics, Inc. | $953M | +1.82% | -27.94% | +51.01% | +164.92% | 17 |
| HELP | Helus Pharma Inc. | $898M | -14.48% | -15.17% | +28.48% | +63.45% | 39 |
| JBIO | Jade Biosciences, Inc. | $894M | -1.99% | -29.20% | -10.76% | +50.66% | 16 |
| PACB | Pacific Biosciences of California, Inc. | $892M | +14.77% | +106.06% | +45.45% | +78.95% | 99 |
| CADL | Candel Therapeutics, Inc. | $884M | -5.94% | -22.06% | +73.81% | +79.52% | 27 |
| RIGL | Rigel Pharmaceuticals, Inc. | $853M | -0.33% | +1.31% | +12.05% | +66.06% | 78 |
| SLBT | SL Science Holding Limited | $852M | -11.18% | -42.37% | -89.81% | -89.62% | 5 |
| AVTX | Avalo Therapeutics, Inc. | $843M | -11.42% | -31.10% | -25.22% | -3.00% | 13 |
| SGP | SpyGlass Pharma, Inc. | $829M | -8.08% | -17.36% | -9.47% | — | 35 |
| SANA | Sana Biotechnology, Inc. | $823M | -6.69% | -21.16% | -33.17% | -34.62% | 28 |
| LXRX | Lexicon Pharmaceuticals, Inc. | $810M | -6.13% | -21.08% | +53.04% | +13.55% | 28 |
| FDMT | 4D Molecular Therapeutics, Inc. | $800M | -12.02% | -13.94% | +67.87% | +49.88% | 42 |
| GYRE | Gyre Therapeutics, Inc. | $776M | -3.96% | -1.81% | -0.28% | -4.09% | 70 |
| ACRS | Aclaris Therapeutics, Inc. | $774M | -35.36% | -43.89% | +12.96% | +82.80% | 4 |
| DSGN | Design Therapeutics, Inc. | $774M | -7.00% | -23.24% | +24.63% | +84.09% | 25 |
| IMMX | Immix Biopharma, Inc. | $744M | -8.79% | -28.38% | +81.45% | +322.72% | 17 |
| SLDB | Solid Biosciences Inc. | $734M | -5.26% | -31.02% | +21.45% | +25.00% | 14 |
| CTKB | Cytek Biosciences, Inc. | $734M | -10.40% | +15.58% | +5.74% | +32.84% | 93 |
| FTH | Faeth Therapeutics, Inc. | $725M | -16.21% | -36.43% | -18.77% | -8.86% | 8 |
| OLMA | Olema Pharmaceuticals, Inc. | $722M | -8.10% | -27.72% | -68.24% | -28.21% | 18 |
| NVCT | Nuvectis Pharma, Inc. | $716M | -3.93% | -15.42% | +168.74% | +235.37% | 38 |
| OABI | OmniAb, Inc. | $715M | -8.06% | +7.55% | +146.49% | +171.43% | 88 |
| ZVRA | Zevra Therapeutics, Inc. | $701M | +1.00% | -12.58% | +23.66% | +4.04% | 45 |
| COLL | Collegium Pharmaceutical, Inc. | $698M | +0.50% | -6.16% | -52.63% | -35.18% | 59 |
| IRWD | Ironwood Pharmaceuticals, Inc. | $656M | -5.54% | -10.07% | +11.28% | +153.38% | 49 |
| GLAS | Glass House Brands Inc. Subordinate Voting Shares | $640M | -8.56% | -38.64% | -42.03% | -36.59% | 7 |
| AURA | Aura Biosciences, Inc. | $638M | +2.87% | -12.23% | +18.53% | +9.12% | 46 |
| SGMT | Sagimet Biosciences Inc. - Series A | $621M | -10.12% | -17.09% | +50.00% | +21.48% | 35 |
| SLN | Silence Therapeutics plc | $610M | -10.16% | -28.27% | +61.51% | +89.21% | 17 |
| AQST | Aquestive Therapeutics, Inc. | $590M | -0.22% | -11.32% | -28.48% | -22.61% | 47 |
| CTMX | CytomX Therapeutics, Inc. | $588M | -6.25% | -30.14% | -40.14% | -22.26% | 15 |
| STTK | Shattuck Labs, Inc. | $568M | -17.08% | -13.00% | +54.93% | +118.34% | 44 |
| MPLT | MapLight Therapeutics, Inc. | $546M | -8.15% | -32.90% | +96.69% | — | 12 |
| EPRX | Eupraxia Pharmaceuticals Inc. | $542M | -14.51% | -7.38% | +3.05% | +32.99% | 55 |
| PHAT | Phathom Pharmaceuticals, Inc. | $542M | -6.71% | -27.78% | -58.95% | -41.34% | 18 |
| AGMB | AgomAb Therapeutics NV - ADRs representing one common share. | $530M | -20.72% | -40.98% | -39.93% | — | 5 |
| EOLS | Evolus, Inc. | $526M | -3.25% | -12.84% | +16.39% | +20.37% | 44 |
| MNPR | Monopar Therapeutics Inc. | $523M | +5.16% | -26.75% | +28.30% | -15.80% | 20 |
| CBIO | Crescent Biopharma, Inc. | $520M | -7.54% | -34.07% | +13.74% | +16.29% | 10 |
| NGNE | Neurogene Inc. | $513M | -7.01% | -32.15% | +25.58% | +12.04% | 12 |
| AUTL | Autolus Therapeutics plc | $508M | -6.70% | -14.22% | -9.05% | +16.03% | 41 |
| DRUG | Bright Minds Biosciences Inc. | $507M | +4.38% | -22.28% | -33.37% | +0.97% | 29 |
| MCTA | Charming Medical Limited | $504M | 0.00% | 0.00% | 0.00% | — | 76 |
| PBYI | Puma Biotechnology Inc | $499M | -1.21% | +4.47% | +64.87% | +95.03% | 85 |
| CAPR | Capricor Therapeutics, Inc. | $498M | -14.47% | -10.60% | -21.01% | -38.04% | 48 |
| ASMB | Assembly Biosciences, Inc. | $488M | -2.30% | -34.95% | -32.52% | -1.59% | 10 |
| CTNM | Contineum Therapeutics, Inc. | $473M | -5.14% | -20.14% | +11.37% | +12.16% | 30 |
| TKNO | Alpha Teknova, Inc. | $468M | -2.13% | +26.60% | +129.21% | +54.16% | 96 |
| ENTX | Entera Bio Ltd. | $466M | -13.75% | -16.61% | -32.34% | -30.91% | 36 |
| OVID | Ovid Therapeutics Inc. | $457M | -5.22% | -14.18% | +44.79% | +31.84% | 41 |
| DMAC | DiaMedica Therapeutics Inc. | $449M | -3.39% | +22.17% | +0.38% | +13.01% | 95 |
| TECX | Tectonic Therapeutic, Inc. | $444M | -2.49% | -25.30% | +8.87% | +49.41% | 23 |
| ZURA | Zura Bio Limited | $442M | +0.24% | -31.97% | -20.42% | 0.00% | 13 |
| SPRY | ARS Pharmaceuticals, Inc. | $434M | +1.16% | -19.11% | -62.58% | -57.55% | 32 |
| EIKN | Eikon Therapeutics, Inc. | $428M | -6.22% | -29.60% | -49.73% | — | 15 |
| TTRX | Turn Therapeutics Inc. | $417M | -15.91% | -4.42% | +207.11% | — | 64 |
| AVIR | Atea Pharmaceuticals, Inc. | $415M | -3.84% | -11.80% | +40.34% | +72.76% | 46 |
| IRD | Opus Genetics, Inc. | $403M | -8.88% | +1.61% | +119.40% | +118.32% | 79 |
| GALT | Galectin Therapeutics Inc. | $394M | -6.70% | -12.56% | -12.98% | -18.47% | 45 |
| EDIT | Editas Medicine, Inc. | $385M | +7.00% | -9.24% | +34.15% | -27.63% | 50 |
| FENC | Fennec Pharmaceuticals Inc. | $379M | -2.72% | -16.79% | +34.55% | +6.37% | 36 |
| ARCT | Arcturus Therapeutics Holdings Inc. | $378M | -6.76% | -18.33% | +108.24% | +13.56% | 34 |
| ARTV | Artiva Biotherapeutics, Inc. | $377M | -1.69% | -35.66% | +63.17% | -42.71% | 9 |
| ENTA | Enanta Pharmaceuticals, Inc. | $367M | -6.15% | -8.37% | -21.56% | +8.99% | 52 |
| CCCC | C4 Therapeutics, Inc. | $367M | -15.32% | -20.56% | +47.64% | +24.23% | 29 |
| OBIO | Orchestra BioMed Holdings, Inc. | $362M | -9.00% | +4.24% | +36.39% | +104.33% | 84 |
| RLMD | Relmada Therapeutics, Inc. | $350M | -13.79% | -23.53% | -32.71% | +56.25% | 25 |
| XFOR | X4 Pharmaceuticals, Inc. | $348M | -3.10% | -19.83% | -29.75% | -16.62% | 30 |
| BNTC | Benitec Biopharma Inc. | $336M | -10.10% | -29.35% | -33.26% | -35.04% | 15 |
| LRMR | Larimar Therapeutics, Inc. | $318M | -13.93% | -32.52% | -27.82% | -42.83% | 12 |
| ABEO | Abeona Therapeutics Inc. | $316M | -3.24% | -15.33% | -3.61% | -6.10% | 39 |
| IPSC | Century Therapeutics, Inc. | $310M | -25.15% | -38.16% | +28.64% | +130.63% | 7 |
| INDP | Indaptus Therapeutics, Inc. | $306M | -1.74% | +22.16% | -63.87% | -67.84% | 95 |
| EVMN | Evommune, Inc. | $304M | -24.70% | -52.45% | -63.67% | — | 2 |
| VNDA | Vanda Pharmaceuticals Inc. | $302M | -7.13% | -14.45% | -48.30% | -15.56% | 41 |
| PRLD | Prelude Therapeutics Incorporated | $300M | -2.05% | -27.74% | +32.07% | +493.22% | 18 |
| LXEO | Lexeo Therapeutics, Inc. | $297M | -2.07% | -30.46% | -66.67% | -48.84% | 15 |
| SRZN | Surrozen, Inc. | $296M | -21.86% | +21.59% | +11.26% | +81.68% | 95 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $293M | -7.94% | -36.72% | +88.89% | +60.38% | 8 |
| CATX | Perspective Therapeutics, Inc. | $288M | -10.55% | -21.15% | -10.55% | -30.70% | 28 |
| IKT | Inhibikase Therapeutics, Inc. | $287M | -5.60% | -20.16% | -5.37% | +19.75% | 30 |
| FATE | Fate Therapeutics, Inc. | $285M | -9.28% | -14.00% | +119.39% | +52.48% | 42 |
| CUVL | Clinuvel Pharmaceuticals Limited | $284M | -2.68% | -3.49% | -31.22% | -29.65% | 66 |
| FULC | Fulcrum Therapeutics, Inc. | $282M | -0.81% | -4.68% | -35.10% | -20.39% | 63 |
| ANIK | Anika Therapeutics Inc. | $273M | -0.66% | -7.18% | +103.23% | +115.33% | 56 |
| RCKT | Rocket Pharmaceuticals, Inc. | $272M | -3.61% | -31.67% | -27.78% | -20.28% | 13 |
| GLSI | Greenwich LifeSciences, Inc. | $270M | -14.74% | -3.21% | -26.75% | +36.44% | 67 |
| SABS | SAB Biotherapeutics, Inc. | $267M | -9.15% | -20.66% | -22.99% | +25.76% | 28 |
| IFRX | InflaRx N.V. | $265M | -13.33% | -28.11% | +54.46% | +3.31% | 17 |
| BCYC | Bicycle Therapeutics plc | $260M | +1.36% | -10.77% | -47.32% | -54.68% | 48 |
| AKBA | Akebia Therapeutics, Inc. | $258M | -5.07% | -15.20% | -45.75% | -70.59% | 39 |
| IVVD | Invivyd, Inc. | $256M | -16.26% | -11.77% | -70.50% | -48.69% | 46 |
| PALI | Palisade Bio, Inc. | $254M | +9.63% | -32.73% | -37.02% | -22.51% | 12 |
| NAUT | Nautilus Biotechnology, Inc. | $249M | +38.03% | +111.23% | +0.51% | +126.59% | 99 |
| LFCR | Lifecore Biomedical, Inc. | $248M | -2.13% | +49.42% | -21.27% | -5.99% | 98 |
| NNNN | Anbio Biotechnology | $244M | -22.22% | -24.38% | -83.70% | -84.22% | 24 |
| HITI | High Tide Inc. | $243M | 0.00% | +1.49% | +3.02% | -23.96% | 79 |
| STRO | Sutro Biopharma, Inc. | $243M | -9.00% | -23.25% | +26.71% | +68.51% | 25 |
| QTTB | Q32 Bio Inc. | $241M | -3.39% | -31.65% | -30.38% | +6.52% | 13 |
| CAMP | CAMP4 Therapeutics Corporation | $241M | -4.95% | -12.73% | -37.36% | +28.86% | 44 |
| PRQR | ProQR Therapeutics N.V. | $236M | -1.81% | -20.49% | -19.31% | -30.93% | 29 |
| SLGL | Sol-Gel Technologies Ltd. | $236M | -3.14% | +3.71% | +70.73% | +67.70% | 83 |
| LYEL | Lyell Immunopharma, Inc. | $231M | -12.56% | -36.73% | -72.19% | -52.04% | 8 |
| WHWK | Whitehawk Therapeutics, Inc. | $230M | -9.31% | -22.32% | +40.91% | +58.60% | 26 |
| MGNX | MacroGenics, Inc. | $229M | -8.03% | -17.82% | +120.50% | +101.70% | 34 |
| LCTX | Lineage Cell Therapeutics, Inc. | $229M | -0.85% | -13.06% | -43.26% | -44.58% | 44 |
| CUE | Cue Biopharma, Inc. | $228M | -12.99% | -24.97% | +19.20% | -49.43% | 23 |
| KROS | Keros Therapeutics, Inc. | $223M | -1.67% | +0.36% | -44.94% | -28.23% | 76 |
| TRDA | Entrada Therapeutics, Inc. | $218M | -11.65% | -25.40% | -45.43% | -5.24% | 22 |
| PLX | Protalix BioTherapeutics, Inc. (DE) | $218M | -1.81% | +2.26% | +50.56% | +4.23% | 81 |
| SION | Sionna Therapeutics, Inc. | $215M | -8.37% | -33.97% | +32.89% | +86.90% | 11 |
| ELDN | Eledon Pharmaceuticals, Inc. | $215M | -4.35% | -17.41% | +60.26% | +68.41% | 35 |
| FOCL | EDAP TMS S.A. - American Depositary Shares, each representing One | $214M | -6.26% | -0.48% | +27.36% | +82.97% | 73 |
| VRXA | Veraxa Biotech AG | $214M | -4.00% | -25.00% | -74.73% | -74.24% | 23 |
| FHTX | Foghorn Therapeutics Inc. | $209M | -41.46% | -56.73% | -61.30% | -53.86% | 1 |
| RNAC | Cartesian Therapeutics, Inc. | $204M | -7.35% | -25.36% | -7.35% | -33.20% | 22 |
| CMPX | Compass Therapeutics, Inc. | $203M | -1.92% | -53.85% | -46.62% | -21.90% | 2 |
| NGEN | NervGen Pharma Corp. | $191M | -8.90% | -20.55% | -68.93% | -42.57% | 29 |
| BNR | Burning Rock Biotech Limited | $190M | -13.90% | +41.74% | -24.67% | +59.79% | 98 |
| VYGR | Voyager Therapeutics, Inc. | $188M | -7.84% | -27.35% | -37.15% | -50.10% | 18 |
| ORMP | Oramed Pharmaceuticals Inc. | $186M | -6.42% | -12.25% | +64.48% | +91.33% | 45 |
| NKTX | Nkarta, Inc. | $184M | -13.36% | -29.72% | +22.70% | +5.58% | 15 |
| ANTX | AN2 Therapeutics, Inc. | $182M | -8.83% | -18.90% | +130.95% | +105.69% | 33 |
| IPHA | Innate Pharma S.A. | $182M | -6.75% | -26.92% | -13.14% | -26.03% | 19 |
| MSLE | Satellos Bioscience Inc. | $180M | -10.24% | -16.88% | +29.76% | +9.44% | 36 |
| MDWD | MediWound Ltd. | $176M | -6.68% | -4.39% | -30.39% | -25.25% | 64 |
| DTIL | Precision BioSciences, Inc. | $172M | -0.16% | -15.54% | +50.24% | +10.23% | 38 |
| ADCT | ADC Therapeutics SA | $167M | +16.39% | +9.23% | -59.77% | -67.95% | 89 |
| ABOS | Acumen Pharmaceuticals, Inc. | $167M | -5.41% | -33.54% | -0.47% | +18.64% | 11 |
| PEPG | PepGen Inc. | $163M | -0.83% | -25.23% | -63.13% | -51.61% | 23 |
| NBP | NovaBridge Biosciences | $157M | +0.37% | -23.03% | -65.58% | -68.29% | 25 |
| NERV | Minerva Neurosciences, Inc | $157M | -2.39% | -25.17% | -18.66% | +55.71% | 23 |
| MENS | Jyong Biotech Ltd. | $154M | +0.49% | -2.83% | -47.85% | -77.37% | 68 |
| TARA | Protara Therapeutics, Inc. | $153M | -15.08% | -33.42% | -51.41% | -46.82% | 11 |
| MOLN | Molecular Partners AG | $151M | -2.56% | -12.41% | -12.59% | +1.60% | 45 |
| KZIA | Kazia Therapeutics Limited | $147M | -3.18% | -24.53% | +34.83% | +41.62% | 24 |
| OTLK | Outlook Therapeutics, Inc. | $145M | +2.88% | -7.88% | -62.66% | -45.87% | 53 |
Next Big Trend kataloğunda Healthcare & Biotech teması ve Next-Gen Biotech Platforms alt teması altında sınıflanan şirketler.
Evet. Giriş yapmış kullanıcılar güncel bileşenleri adlı bir izleme listesi olarak kaydedebilir.
Hayır. Tarama için araştırma evrenidir, tavsiye değildir.